Evergreen · By Jacob Teague · · Updated

What people mean by BPC-157 and TB-500

People often say the two names in one breath. They are different substances. Neither is an FDA-approved drug.

BPC-157 is a synthetic fragment related to a body-protection compound studied mainly in animals. TB-500 is the name people use for a thymosin-beta-4 fragment. That is the naming, not a mechanism, and not a healing claim.

At the July 23, 2026 meeting of FDA’s Pharmacy Compounding Advisory Committee, the committee recommended both for the 503A Bulks List, 8–6 with 1 abstention. FDA staff had recommended against. The vote does not legalize compounding and does not approve either drug.

Update, November 11, 2026. On October 30, 2026, HHS published a draft enforcement discretion policy for compounding certain peptides. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds with a peptide on its list while the 503A Bulks List is developed through rulemaking. Law-firm summaries of the policy list the same six peptides the committee backed (BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500) and ten conditions, including a valid patient-specific prescription. Outsourcing facilities are not covered. The policy does not approve any peptide, does not add any peptide to the Bulks List, and is not binding. HHS says it may revisit it if a safety or quality problem arises. Comments were due November 13, 2026. None of these peptides is an FDA-approved drug.

BPC-157 was evaluated at that meeting for ulcerative colitis. TB-500 was evaluated for wound healing. Those are the uses the committee discussed — not a menu of what to take.

A tracker can hold the name you logged. It cannot tell you what to take. The news write-up is here: An FDA panel voted on six peptides. That is not approval.

Citations

Peptide Vault is a personal log and research library. Not medical advice, not a pharmacy, not a shop. We do not tell you what to take or where to get it. No dosing. No where-to-buy. No mix tutorials. No heal/optimize claims.

Optional

Peptide brief

Weekly. What changed. What isn’t approved.

Optional. Weekly if we send it. Not a protocol.